UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 192,964 Shares of Ralliant Corporation $RAL

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its holdings in shares of Ralliant Corporation (NYSE:RAL) by 39.1% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 299,980 shares of the company’s stock after selling 192,964 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.27% of Ralliant worth $22,088,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of RAL. BlackRock Inc. acquired a new stake in shares of Ralliant during the second quarter valued at about $1,039,481,000. Irenic Capital Management LP grew its holdings in shares of Ralliant by 424.1% during the first quarter. Irenic Capital Management LP now owns 1,740,218 shares of the company’s stock worth $72,376,000 after purchasing an additional 1,408,176 shares during the last quarter. Rokos Capital Management LLP acquired a new position in shares of Ralliant in the first quarter valued at approximately $42,022,000. Flossbach Von Storch SE acquired a new position in shares of Ralliant in the second quarter valued at approximately $222,460,000. Finally, Sei Investments Co. raised its holdings in Ralliant by 193.7% in the 1st quarter. Sei Investments Co. now owns 182,342 shares of the company’s stock valued at $7,583,000 after buying an additional 120,248 shares during the last quarter.

Ralliant Stock Up 1.1%

Ralliant stock opened at $63.46 on Friday. The firm has a market cap of $7.02 billion, a price-to-earnings ratio of -5.85, a PEG ratio of 2.33 and a beta of 1.54. Ralliant Corporation has a 52-week low of $37.27 and a 52-week high of $75.41. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.00 and a current ratio of 1.52. The firm has a 50 day moving average price of $67.52 and a two-hundred day moving average price of $57.10.

Ralliant (NYSE:RAL) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.63 by $0.05. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. The company had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Equities analysts predict that Ralliant Corporation will post 2.87 EPS for the current year.

Ralliant Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Ralliant’s dividend payout ratio is -1.84%.

Insiders Place Their Bets

In other news, SVP Karen M. Bick sold 6,062 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $72.00, for a total value of $436,464.00. Following the transaction, the senior vice president directly owned 31,668 shares of the company’s stock, valued at $2,280,096. The trade was a 16.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Tamara S. Newcombe sold 12,936 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $71.79, for a total value of $928,675.44. Following the sale, the chief executive officer owned 251,967 shares in the company, valued at approximately $18,088,710.93. The trade was a 4.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.42% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on RAL. Oppenheimer lifted their target price on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 13th. Truist Financial reaffirmed a “buy” rating and set a $82.00 price target (up from $68.00) on shares of Ralliant in a research note on Friday, July 31st. BMO Capital Markets started coverage on shares of Ralliant in a report on Monday, July 20th. They set a “market perform” rating and a $78.00 price target on the stock. Royal Bank Of Canada boosted their price objective on shares of Ralliant from $71.00 to $73.00 and gave the stock a “sector perform” rating in a research note on Friday, July 31st. Finally, Wall Street Zen lowered Ralliant from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 30th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $75.70.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.